Amazon and Apple Results; Nvidia Hopes to Sell Blackwell Chips to China | Bloomberg Brief 10/31/2025

The Bloomberg Brief highlights strong tech earnings from Apple and Amazon, Nvidia’s strategic partnerships in South Korea, and its ambitions to sell advanced chips to China despite export challenges, alongside a competitive pharmaceutical bidding war involving Pfizer and Novo Nordisk. Market sentiment remains cautiously optimistic amid mixed economic data, ongoing U.S. government shutdown impacts, and geopolitical tensions, with upcoming energy earnings and Federal Reserve decisions poised to influence near-term market direction.

The Bloomberg Brief opens with a focus on major tech earnings, highlighting Apple’s optimistic outlook for a blockbuster holiday season and Amazon’s fastest growth in years, driven by its cloud unit AWS and AI capabilities. Despite some market jitters, Amazon’s cloud business posted a 20% growth, dispelling concerns about losing AI market share to rivals like Google and Microsoft. Apple also showed strength, particularly with iPhone sales expected to rise 10-12% during the holiday quarter, signaling a recovery in the China market. Netflix announced a 10-for-1 stock split and is reportedly considering a bid for Warner Bros., boosting its shares alongside Warner Bros.

Nvidia made significant strides in Asia by forging partnerships with South Korea’s largest companies, including Samsung Electronics, Hyundai Motors, and SK Group, to build AI infrastructure and develop GPU production. CEO Jensen Huang expressed hopes to sell Nvidia’s advanced Blackwell chips to China, although export restrictions and geopolitical tensions complicate this prospect. The deals with South Korean firms are binding partnerships aimed at embedding Nvidia’s technology deeply into the region’s AI ecosystem, reflecting a strategic move amid restrictions on sales to China.

In the pharmaceutical sector, Pfizer faces a critical moment with only four days to make a better offer than Novo Nordisk’s $6.5 billion bid to acquire a drugmaker specializing in obesity treatments. The deal is seen as vital for Pfizer to strengthen its pipeline amid investor pressure, while concerns linger about potential overpayment. Novo Nordisk’s aggressive approach and American company status add complexity to the bidding war, with Pfizer’s next moves closely watched by the market.

Market analysis from BNP Paribas highlights a cautious but pro-risk stance despite weaker U.S. economic data and ongoing government shutdown impacts. Earnings reports have generally exceeded expectations, supporting positive sentiment, though volatility is expected as the Federal Reserve’s future rate decisions remain uncertain. The bond market shows signs of a steepening yield curve, and gold is seen as potentially forming a base for renewed safe-haven demand. The government shutdown, now in its 31st day, continues to weigh on certain sectors, particularly with SNAP benefits halted and uncertainty around federal employee pay.

The briefing also covers geopolitical and policy developments, including Japan’s balancing act between the U.S. and China following recent summit talks, and the Trump administration’s push for a global internet free of digital service taxes, which faces skepticism in Europe. The government shutdown remains unresolved, with no immediate solution in sight as Congress remains out of session. Upcoming earnings from Exxon and Chevron, along with continued Fed commentary, are expected to influence market direction in the near term. Overall, the briefing paints a picture of cautious optimism driven by strong tech earnings and strategic corporate moves amid a complex macroeconomic and geopolitical landscape.